Daniel Salain Net Worth

Mr. Daniel Salain biography

Daniel Salain is the Chief Technical Operations Officer at Graybug Vision.

What is the salary of Mr Salain?

As the Chief Technical Operations Officer of Graybug Vision, the total compensation of Mr Salain at Graybug Vision is $509,420. There are 1 executives at Graybug Vision getting paid more, with Dr. Frederic Guerard Pharm.D. having the highest compensation of $931,025.

How old is Mr Salain?

Mr Salain is 52, he's been the Chief Technical Operations Officer of Graybug Vision since . There are 6 older and 1 younger executives at Graybug Vision. The oldest executive at Graybug Vision, Inc. is Dr. Gerald D. Cagle Ph.D., 77, who is the Sr. Advisor, Head of Bus. Devel. & Director.

What's Mr Salain's mailing address?

Daniel's mailing address filed with the SEC is C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., EXTON, PA, 19341.

Insiders trading at Graybug Vision

Over the last 4 years, insiders at Graybug Vision have traded over $0 worth of Graybug Vision stock and bought 2,393,750 units worth $38,300,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., James E Deerfield Mgmt Hif,..., and Frederic Guerard. On average, Graybug Vision executives and independent directors trade stock every 35 days with the average trade being worth of $720,841. The most recent stock trade was executed by Robert S Breuil on 14 March 2023, trading 5,000 units of GRAY stock currently worth $27,500.

What does Graybug Vision do?

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Graybug Vision executives and stock owners

Graybug Vision executives and other stock owners filed with the SEC include:

• Dr. Frederic Guerard Pharm.D.,
  Pres, CEO, Sec. & Director
• Daniel Salain,
  Chief Technical Operations Officer
• Dr. Parisa Zamiri M.D., Ph.D.,
  Chief Medical Officer
• Robert S. Breuil,
  Chief Financial Officer
• Dr. Gerald D. Cagle Ph.D.,
  Sr. Advisor, Head of Bus. Devel. & Director
• Dr. Peter J. McDonnell M.D.,
  Co-Founder
• Ali Kakavand,
  VP & Head of Program Management
• Ming Yang,
  Sr. VP of R&D
• Dr. Peter A. Campochiaro M.D.,
  Co-Founder
• Dr. Ward M. Peterson Ph.D.,
  Sr. VP of Preclinical Devel.
• Bettina Maunz,
  Chief People Officer & Head of Communications
• Dr. Peter J. McDonnell,
  Co-Founder
• Dr. Peter A. Campochiaro,
  Co-Founder
• Dr. Gerald D. Cagle,
  Sr. Advisor, Head of Bus. Devel. & Director
• Christina Ackermann,
  Director
• Eric Bjerkholt,
  Director
• Robert S Breuil,
  Chief Financial Officer
• Julia Marie Eastland,
  Director
• Gerald D. Cagle,
  Director
• Daniel Salain,
  CTOO
• Hansoo Michael Keyoung,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Christy L Shaffer,
  Director
• Lifesciences Iii, L.P.Claru...,
  
• James E Deerfield Mgmt Hif,...,
  
• Frederic Guerard,
  Chief Executive Officer
• Parisa Zamiri,
  Chief Medical Officer
• Dirk Sauer,
  Director